Oncolix, Inc, Continues Progress as an Emerging Clinical-Stage Biopharmaceutical Company with Stock Ticker Symbol Change to O...
November 28 2017 - 10:26AM
Marketwired
Oncolix, Inc. OTC PINK : AEPP
|
November 28, 2017 10:26 ET
Oncolix, Inc., Continues Progress as an Emerging Clinical-Stage
Biopharmaceutical Company with Stock Ticker Symbol Change to
ONCX
New symbol becomes effective at opening of trading on November
29, 2017
HOUSTON, TEXAS--(Marketwired - Nov. 28, 2017) - Oncolix,
Inc., (OTC PINK:AEPP) announced today that the Financial Industry
Regulatory Authority (FINRA) has approved a change in the Company's
stock symbol to ONCX, effective at the opening of trading on
November 29, 2017. The ticker symbol change is continued
demonstration of progress toward positioning Oncolix as an emerging
biopharmaceutical company with a clinical-stage asset.
"We are very much committed to building an innovative
biopharmaceutical company and to furthering the development of
Prolanta, which is currently in an ongoing Phase I human clinical
trial in ovarian cancer patients," said Michael T. Redman, chief
executive officer of Oncolix. "The ticker and name change and the
recent appointment of an independent director on our board are
continued evidence of our progress as a clinical-stage
biopharmaceutical company. These are also important steps as we
continue to build out the public company infrastructure to fulfill
the OTC-QB listing requirements and ultimately a NASDAQ
listing."
About Oncolix
Oncolix is a clinical-stage biotechnology company developing
Prolanta for the treatment of ovarian, uterine, breast and other
cancers. The Company has a US FDA-cleared IND to commence human
testing of Prolanta in its first indication, the treatment of
ovarian cancer. This Phase 1 clinical trial is currently in
progress. Prolanta is a prolactin receptor antagonist (or blocker)
that has demonstrated efficacy in xenograft models through a unique
mechanism of action, autophagy. In addition to ovarian cancer,
there is strong preclinical evidence Prolanta may be effective in
breast, prostate and other cancers. In the current Phase 1
dose-escalation safety trial for the treatment of ovarian cancer,
to date there have been no observed serious adverse events and no
dose-limiting toxicities. The FDA has approved the designation of
Prolanta as an Orphan Drug for the treatment of ovarian cancer,
which may result in reduced filing fees (currently $2 million),
federal tax credits and marketing exclusivity.
Forward-Looking Statements
This press release above may contain forwardlooking statements
about the business, financial condition and prospects of the
Company. Forward looking statements can be identified by the use of
forward-looking terminology such as "believes," "projects,"
"expects," "may," "goal," "estimates," "should," "plans,"
"targets," "intends," "could," or "anticipates," or the negative
thereof, or other variations thereon, or comparable terminology, by
discussions of strategy or objectives. Forward-looking statements
relate to anticipated or expected events, activities, trends or
results. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties.
Although the Company believes that the expectations reflected in
forward-looking statements are reasonable, there can be no
assurances that such expectations will prove to be accurate.
Security holders are cautioned that such forward-looking statements
involve risks and uncertainties. The forward-looking statements
contained in the press release speak only as of the date of the
press release, and the Company expressly disclaims any obligation
or undertaking to report any updates or revisions to any such
statement to reflect any change in the Company's expectations or
any change in events, conditions or circumstances on which any such
statement is based. Certain factors may cause results to differ
materially from those anticipated by some of the statements made in
the press release. Investors are urged to consider closely the
disclosures in our Forms 10-K, 10-Q, 8-K and other filings with the
SEC, which can be electronically accessed from the SEC's website
at http://www.sec.gov/.
CONTACT INFORMATION
Corporate contact:Michael RedmanP:
281-402-3167E: mredman@oncolixbio.comInvestor contact:The Ruth
GroupRobert Flamm, Ph.D.P:
646-536-7017E: rflamm@theruthgroup.com